Latest News from Origin
Origin Capital co-leads £2.1m investment in platform biotech Somaserve
Origin Capital was the largest investor in a £2.1m funding round recently completed by Somaserve, a developer of specialised nanoparticle technologies for delivery of pharmaceutical and other therapeutic agents to targeted cell types. Read more here.
CyTAL secures investment from Origin Capital
We have made a significant investment in CyTAL, a provider of cybersecurity product assurance services. The funding will support CyTAL’s accelerated growth plans for ProtoCrawler, its specialist “fuzz-testing” software application, used for identifying vulnerabilities in a wide range of connected devices. Read more here.
Origin Capital News: Q3 2020
We have published our latest newsletter! See here.
